RxDoctor Payments Data

Michael Mansour, MD

Interventional Cardiology · Mobile, ALNPI 1326077058

Payments from drug & device makers

$1,057in general payments, 2019–2025

Across 47 payments — averaging $22.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$170
  • E.r. Squibb & Sons, L.L.C.$153
  • Penumbra, Inc.$132
  • Johnson & Johnson$121
  • Abbott$96
  • GE HealthCare$67
  • plus $317 from 10 others

What the payments were for

  • Food & beverage$1,057100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,057 in reported general payments places this provider in the 10th percentile of 109 interventional cardiology providers in Alabama.

See all interventional cardiology providers in Alabama

Medicare billing

Part B allowed, 2024
$120,521
Medicare patients
620
Services billed
8,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban84$76,346
XareltoRivaroxaban27$25,546
JardianceEmpagliflozin21$14,880
EntrestoSacubitril/Valsartan11$11,513
BrilintaTicagrelor27$11,424
Atorvastatin Calcium130$1,552
Ezetimibe54$1,133
Losartan Potassium95$993
Diltiazem 24hr Er (Cd)Diltiazem Hcl46$924
Pindolol12$805
Amiodarone Hcl71$754
Ranolazine ErRanolazine11$731
Metoprolol Succinate77$722
Isosorbide Dinitrate18$692
Carvedilol86$682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$170$76,34684 claims
Johnson & JohnsonXarelto$121$25,54627 claims
NovartisEntresto$15$11,51311 claims
AstraZenecaBrilinta$43$11,42427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 10th percentile of 109 interventional cardiology providers in Alabama.

Other interventional cardiology in Mobile

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →